DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2013/0040942 A1 Cowen Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2013/0040942 A1 Cowen Et Al US 2013 004O942A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0040942 A1 COWen et al. (43) Pub. Date: Feb. 14, 2013 (54) SALTS OF POTASSIUM ATP CHANNEL Publication Classification OPENERS AND USES THEREOF (51) Int. Cl. (75) Inventors: Neil M. Cowen, San Diego, CA (US); A63/549 (2006.01) Iain Dukes. Durham, NC (US) A6IP5/00 (2006.01) A6IP3/08 (2006.01) (73) Assignee: Essentialis, Inc. A6IP3/06 (2006.01) (52) U.S. Cl. .................................. 514/223.5: 514/223.2 Appl. No.: 13/543,665 (21) (57) ABSTRACT (22) Filed: Jul. 6, 2012 Provided are immediate or prolonged administration of cer tain salts of K channel openers such as diazoxide to a Related U.S. Application Data Subject to achieve novel pharmacodynamic, pharmacoki netic, therapeutic, physiological, metabolic and composi (63) Continuation of application No. 12/166,251, filed on tional outcomes in the treatment of diseases or conditions Jul. 1, 2008, now abandoned. involving K channels. Also provided are pharmaceutical (60) Provisional application No. 60/947,628, filed on Jul. 2, formulations, methods of administration and dosing of the 2007, provisional application No. 60/949,207, filed on salts that achieve these outcomes and reduce the incidence of Jul. 11, 2007, provisional application No. 60/950,854, adverse effects in treated individuals. Further provided are filed on Jul. 19, 2007, provisional application No. method of co-administering the salts with other drugs to treat 60/986,251, filed on Nov. 7, 2007. diseases of humans and animals. Patent Application Publication Feb. 14, 2013 Sheet 1 of 51 US 2013/004O942 A1 a S. 8 a II Š 8 C 2 N1 ?h al W / s. / 8 c E C V C 9 g o s CN C CN CN S CN Patent Application Publication Feb. 14, 2013 Sheet 2 of 51 US 2013/004O942 A1 CN O) v. CN Y LO O). OO CO cy) V. co Lo o co co O O. O LO CO. N. N. OO CO. O. S. O. O. O. O. O. O. O. ii O CN cy eaE CN Oo S. c5 * C CD O) D (A OO is CN O CO CN O N CN eouedoSCW Patent Application Publication Feb. 14, 2013 Sheet 3 of 51 US 2013/004O942 A1 C. ri 9 | S is | N to its . 2 Y ------swer-e-rror.0 C Patent Application Publication Feb. 14, 2013 Sheet 4 of 51 US 2013/004O942 A1 S.g & axerxes |: o s s s C Patent Application Publication Feb. 14, 2013 Sheet 5 of 51 US 2013/004O942 A1 +00G| gri-rr g- ro------- 000z 000L (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 6 of 51 US 2013/004O942 A1 x S. S3 g & -3. 2 Sp (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 7 of 51 US 2013/004O942 A1 |0 000€ 000z |000|| (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 8 of 51 US 2013/004O942 A1 s Patent Application Publication Feb. 14, 2013 Sheet 9 of 51 US 2013/004O942 A1 g Patent Application Publication Feb. 14, 2013 Sheet 10 of 51 US 2013/004O942 A1 E Cl C. - S. to o o v Lo C g s Patent Application Publication Feb. 14, 2013 Sheet 11 of 51 US 2013/004O942 A1 5.g3S. o Se s (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 12 of 51 US 2013/0040942 A1 s rt - - - - S. i to cr) Cd cr) a. O s 3-XMPomaroaM it- u?N 9.is s O c O s s CD H Ot r e Lo s (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 13 of 51 US 2013/004O942 A1 st R 5 CN. F to Y E cd () es EsM S.o E N w9. E 9O N MWramrox =S CD E to 9 s C (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 14 of 51 US 2013/0040942 A1 Patent Application Publication Feb. 14, 2013 Sheet 15 of 51 US 2013/0040942 A1 l S - š ss5 g Patent Application Publication Feb. 14, 2013 Sheet 16 of 51 US 2013/004O942 A1 C O C O O C C v- t (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 17 of 51 US 2013/004O942 A1 o O C O C C C O C 2 C r N (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 18 of 51 US 2013/004O942 A1 C C d O O O O O O C 2 O CO v N (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 19 of 51 US 2013/004O942 A1 S Patent Application Publication Feb. 14, 2013 Sheet 20 of 51 US 2013/004O942 A1 O c O r s s (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 21 of 51 US 2013/004O942 A1 C O C O d C C C O C O 2 o r N (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 22 Of 51 US 2013/0040942 A1 rw sC o: come saunc s O { Patent Application Publication Feb. 14, 2013 Sheet 23 of 51 US 2013/0040942 A1 o CO v C (d v d w w v O 5v CD d C d Patent Application Publication Feb. 14, 2013 Sheet 24 of 51 US 2013/004O942 A1 ggS.g & i 2 2 Patent Application Publication Feb. 14, 2013 Sheet 25 of 51 US 2013/004O942 A1 C C (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 26 of 51 US 2013/004O942 A1 g (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 27 of 51 US 2013/004O942 A1 C L? ? c O Lo O C n - O N - 860 e c- 480 Patent Application Publication Feb. 14, 2013 Sheet 28 of 51 US 2013/004O942 A1 E5. - Cl L C o - i - =(&O - in y O ranama S-(460C 60 - 3. 3. Patent Application Publication Feb. 14, 2013 Sheet 29 of 51 US 2013/004O942 A1 i s Patent Application Publication Feb. 14, 2013 Sheet 30 of 51 US 2013/0040942 A1 X& sax. 3 Co r $. s: to is 92 c. e sa s: O FE g. X CY C wd smas 9. L H N CD Momm LL H w wa C - wa C C C C C 32 COS CC3 w S (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 31 of 51 US 2013/004O942 A1 g S. s g & - S. 2 s (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 32 of 51 US 2013/004O942 A1 g O v (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 33 of 51 US 2013/004O942 A1 w s S. r E cy)o an isN 9is V (N =5E 2GD CD t L Lo E. ve C vet (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 34 of 51 US 2013/004O942 A1 (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 35 of 51 US 2013/004O942 A1 (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 36 Of 51 US 2013/0040942 A1 s G 8 O S Patent Application Publication Feb. 14, 2013 Sheet 37 of 51 US 2013/0040942 A1 E d o 90 on OO co - - 39 66 w r 2 Patent Application Publication Feb. 14, 2013 Sheet 38 of 51 US 2013/004O942 A1 g s S 3s - 9. CC w & N CD tails S. - 2 s O3 So 8 te year (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 39 of 51 US 2013/004O942 A1 V O V O (Y) O cy S m L?) OO Q is V rks ci rO (N LL Xwas to H O s O Patent Application Publication Feb. 14, 2013 Sheet 40 of 51 US 2013/004O942 A1 Patent Application Publication Feb. 14, 2013 Sheet 41 of 51 US 2013/004O942 A1 S. 2 9 C O N Patent Application Publication Feb. 14, 2013 Sheet 42 of 51 US 2013/004O942 A1 | Patent Application Publication Feb. 14, 2013 Sheet 43 of 51 US 2013/004O942 A1 S. as: S o 9 i - Fe s (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 44 of 51 US 2013/004O942 A1 (6æp)e???LZ-e???L |0||G09GZOZG ?-!!!!!!!!!!!!1111111,! 0 000|| 00C (Sdo) Patent Application Publication Feb. 14, 2013 Sheet 45 of 51 US 2013/0040942 A1 S. r ( ve O O ve O C CO wif isi? a . e s 2 s 3 &Og gR. sC. t- ----- | Patent Application Publication Feb. 14, 2013 Sheet 46 of 51 US 2013/0040942 A1 s Patent Application Publication Feb. 14, 2013 Sheet 47 of 51 US 2013/004O942 A1 ZZ"SDI O O r CN v v 00|| (6H uu) enssel pool Patent Application Publication Feb. 14, 2013 Sheet 48 of 51 US 2013/004O942 A1 i O O. O. O. O. O. O. O. O. O. O. O O OO N CO LO v Crd CN Y r (uu/Speed) eSn Patent Application Publication Feb. 14, 2013 Sheet 49 of 51 US 2013/004O942 A1 7Z"SOIH Z| 90 (uffr) ep)xOZeO Patent Application Publication Feb. 14, 2013 Sheet 50 of 51 US 2013/004O942 A1 OZ||780Z0||9606788/Z/99097987Z?7980£7Z (uu)?uu?L 92"SDI 9 0 (u/6rl) epixOZeO Patent Application Publication Feb. 14, 2013 Sheet 51 of 51 US 2013/004O942 A1 N.QsoN 9 O O. O. O. O. D. O. D. O r of CYO CN CN V V (u?br) epixOZeO euSel US 2013/004O942 A1 Feb. 14, 2013 SALTS OF POTASSIUM ATP CHANNEL larization, thereby preventing voltage-dependent Ca" chan OPENERS AND USES THEREOF nels (VDCCs) from opening.
Load more

Recommended publications
  • Molecular Mechanisms Underlying Ketamine-Mediated Inhibition Of
    Anesthesiology 2005; 102:93–101 © 2004 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Molecular Mechanisms Underlying Ketamine-mediated Inhibition of Sarcolemmal Adenosine Triphosphate- sensitive Potassium Channels Takashi Kawano, M.D.,* Shuzo Oshita, M.D.,† Akira Takahashi, M.D.,‡ Yasuo Tsutsumi, M.D.,* Katsuya Tanaka, M.D.,§ Yoshinobu Tomiyama, M.D.,࿣ Hiroshi Kitahata, M.D.,# Yutaka Nakaya, M.D.** Background: Ketamine inhibits adenosine triphosphate-sen- sensitive channel pore.3 These channels, as metabolic sitive potassium (KATP) channels, which results in the blocking sensors, are associated with such cellular functions as of ischemic preconditioning in the heart and inhibition of va- insulin secretion, cardiac preconditioning, vasodilata- sorelaxation induced by KATP channel openers. In the current 4–7 Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/102/1/93/357819/0000542-200501000-00017.pdf by guest on 27 September 2021 study, the authors investigated the molecular mechanisms of tion, and neuroprotection. ketamine’s actions on sarcolemmal KATP channels that are re- In cardiac myocytes, intravenous general anesthetics, associated by expressed subunits, inwardly rectifying potas- such as ketamine racemate, propofol, and thiamylal, di- sium channels (Kir6.1 or Kir6.2) and sulfonylurea receptors 8–10 rectly inhibit native sarcolemmal KATP channels. Al- (SUR1, SUR2A, or SUR2B). though these observations suggest that intravenous an- Methods: The authors used inside-out patch clamp configura- tions to investigate the effects of ketamine on the activities of esthetics may impair the endogenous organ protective reassociated Kir6.0/SUR channels containing wild-type, mutant, mechanisms mediated by KATP channels, the possibility or chimeric SURs expressed in COS-7 cells.
    [Show full text]
  • Iatrogenic Misadventure
    BRITISH MEDICAL JOURNAL 18 MARcH 1972 733 Scientific Basis of Clinical Practice Br Med J: first published as 10.1136/bmj.1.5802.733 on 18 March 1972. Downloaded from Iatrogenic Misadventure A. G. W. WHITFIELD British Medical journal, 1972, 1, 733-734 effects. No one would pretend that our knowledge of drugs interacting with oral anticoagulants is complete. Even so, A striking feature of the history of therapeutics is the extent to sufficient is already known to indicate that anticoagulant drugs which fashion, rather than clinical science, governs the treat- have potent dangers and should be used only within the limited ment we mete out to our patients. Some ten years ago I attended sphere in which they are of proven worth. Moreover, when they a symposium on anticoagulant therapy and returned home are given, if possible, no other drug should be given at the firmly convinced that in all but a very few conditions such same time as many are known to inhibit or enhance their effect treatment was absolutely essential and indeed it was little short and many others may have similar interactions, even though of criminal negligence to withhold it. At that time the patient these are as yet unrecognized and unreported. queue for "prothrombin times" was usually the longest in our hospitals and phenindione was among the most frequently prescribed drugs, but our constant use of it stemmed from enthusiasm and ignorance of its dangers and not from scientific Hypotensive Drugs proof of its therapeutic advantages. Indeed it is only as know- Hypotensive drugs are being used increasingly and undoubtedly ledge has accumulated that we have learned of the toxic effects, their development has provided an enormous advance both in of the drug we gave so freely, on the kidney, the liver, the bone the treatment and in the prognosis of the severe forms of marrow, and the skin and that except in thromboembolic disease and in patients with hypertension-particularly in the younger age groups.
    [Show full text]
  • Potassium Channels in Peripheral Pain Pathways: Expression, Function and Therapeutic Potential
    Send Orders for Reprints to [email protected] Current Neuropharmacology, 2013, 11, 621-640 621 Potassium Channels in Peripheral Pain Pathways: Expression, Function and Therapeutic Potential Xiaona Du1,* and Nikita Gamper1,2,* 1Department of Pharmacology, Hebei Medical University, Shijiazhuang, China; 2Faculty of Biological Sciences, University of Leeds, Leeds, UK Abstract: Electrical excitation of peripheral somatosensory nerves is a first step in generation of most pain signals in mammalian nervous system. Such excitation is controlled by an intricate set of ion channels that are coordinated to produce a degree of excitation that is proportional to the strength of the external stimulation. However, in many disease states this coordination is disrupted resulting in deregulated peripheral excitability which, in turn, may underpin pathological pain states (i.e. migraine, neuralgia, neuropathic and inflammatory pains). One of the major groups of ion channels that are essential for controlling neuronal excitability is potassium channel family and, hereby, the focus of this review is on the K+ channels in peripheral pain pathways. The aim of the review is threefold. First, we will discuss current evidence for the expression and functional role of various K+ channels in peripheral nociceptive fibres. Second, we will consider a hypothesis suggesting that reduced functional activity of K+ channels within peripheral nociceptive pathways is a general feature of many types of pain. Third, we will evaluate the perspectives of pharmacological enhancement of K+ channels in nociceptive pathways as a strategy for new analgesic drug design. + + Keywords: K channel/ M channel/ two-pore K channel/ KATP channel/ Dorsal root ganglion/ Pain/ Nociception. INTRODUCTION TRPV1 [4] while strong mechanical stimulation activates mechanosensitive channels which can be Piezo2 [5].
    [Show full text]
  • Label-Free Cell Phenotypic Profiling Decodes the Composition And
    OPEN Label-free cell phenotypic profiling SUBJECT AREAS: decodes the composition and signaling POTASSIUM CHANNELS SENSORS AND PROBES of an endogenous ATP-sensitive Received potassium channel 28 January 2014 Haiyan Sun1*, Ying Wei1, Huayun Deng1, Qiaojie Xiong2{, Min Li2, Joydeep Lahiri1 & Ye Fang1 Accepted 24 April 2014 1Biochemical Technologies, Science and Technology Division, Corning Incorporated, Corning, NY 14831, United States of Published America, 2The Solomon H. Snyder Department of Neuroscience and High Throughput Biology Center, Johns Hopkins University 12 May 2014 School of Medicine, Baltimore, Maryland 21205, United States of America. Current technologies for studying ion channels are fundamentally limited because of their inability to Correspondence and functionally link ion channel activity to cellular pathways. Herein, we report the use of label-free cell requests for materials phenotypic profiling to decode the composition and signaling of an endogenous ATP-sensitive potassium should be addressed to ion channel (KATP) in HepG2C3A, a hepatocellular carcinoma cell line. Label-free cell phenotypic agonist Y.F. (fangy2@corning. profiling showed that pinacidil triggered characteristically similar dynamic mass redistribution (DMR) com) signals in A431, A549, HT29 and HepG2C3A, but not in HepG2 cells. Reverse transcriptase PCR, RNAi knockdown, and KATP blocker profiling showed that the pinacidil DMR is due to the activation of SUR2/ Kir6.2 KATP channels in HepG2C3A cells. Kinase inhibition and RNAi knockdown showed that the pinacidil * Current address: activated KATP channels trigger signaling through Rho kinase and Janus kinase-3, and cause actin remodeling. The results are the first demonstration of a label-free methodology to characterize the Biodesign Institute, composition and signaling of an endogenous ATP-sensitive potassium ion channel.
    [Show full text]
  • Australian Public Assessment Report for Fampridine
    Australian Public Assessment Report for Fampridine Proprietary Product Name: Fampyra Sponsor: Biogen Idec Australia Pty Ltd June 2011 About the Therapeutic Goods Administration (TGA) · The TGA is a division of the Australian Government Department of Health and Ageing, and is responsible for regulating medicines and medical devices. · TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website. About AusPARs · An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. · AusPARs are prepared and published by the TGA. · An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. · An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. · A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • Thiruttu Tuomittur
    THIRUTTUUS009782416B2 TUOMITTUR (12 ) United States Patent ( 10 ) Patent No. : US 9 ,782 ,416 B2 Cowen (45 ) Date of Patent: Oct. 10 , 2017 ( 54 ) PHARMACEUTICAL FORMULATIONS OF 4 , 880 , 830 A 11/ 1989 Rhodes POTASSIUM ATP CHANNEL OPENERS AND 4 ,894 , 448 A 1 / 1990 Pelzer 5 ,063 , 208 A 11/ 1991 Rosenberg et al . USES THEREOF 5 , 284 ,845 A 2 / 1994 Paulsen 5 ,356 ,775 A 10 / 1994 Hebert et al . (71 ) Applicant: Essentialis , Inc. , Carlsbad , CA (US ) 5 ,376 , 384 A 12 / 1994 Eichel et al. 5 , 378 , 704 A 1 / 1995 Weller, III (72 ) Inventor: Neil Madison Cowen , Carlsbad , CA 5 , 399 , 359 A 3 / 1995 Baichwal 5 ,415 , 871 A 5 / 1995 Pankhania et al . (US ) 5 ,629 , 045 A 5 / 1997 Veech 5 , 733 , 563 A 3 / 1998 Fortier (73 ) Assignee : Essentialis , Inc. , Redwood City , CA 5 , 744 , 594 A 4 / 1998 Adelman et al . (US ) 5 , 965 ,620 A 10 / 1999 Sorgente et al . 6 ,022 , 562 A 2 /2000 Autant et al . 6 , 140 , 343 A 10 / 2000 Deninno et al . ( * ) Notice : Subject to any disclaimer , the term of this 6 , 146 ,662 A 11/ 2000 Jao et al . patent is extended or adjusted under 35 6 , 197, 765 B1 3 / 2001 Vardi et al. U . S . C . 154 (b ) by 0 days . 6, 197, 976 B1 3 / 2001 Harrington et al . 6 , 225, 310 B1 5 / 2001 Nielsen et al. (21 ) Appl. No. : 14 / 458 ,032 6 , 255 , 459 B1 7 / 2001 Lester et al . 6 , 277, 366 B1 8 / 2001 Goto et al .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • USP–NF 2021, Issue 1 Commentary
    Commentary USP–NF 2021 Issue 1 November 2, 2020 In accordance with USP’s Rules and Procedures of the Council of Experts (“Rules”), and except as provided in Section 9.02 Accelerated Revision Processes, USP publishes proposed revisions to the United States Pharmacopeia and the National Formulary (USP–NF) for public review and comment in the Pharmacopeial Forum (PF), USP’s free bimonthly journal for public notice and comment. After comments are considered and incorporated as the Expert Committee deems appropriate, the proposal may advance to official status or be re-published in PF for further notice and comment, in accordance with the Rules. In cases when proposals advance to official status, a summary of comments received and the appropriate Expert Committee's responses, as well as Expert Committee-initiated changes, are published in the Proposal Status/Commentary section of USPNF.com at the time the official revision is published. The Commentary is not part of the official text and is not intended to be enforceable by regulatory authorities. Rather, it explains the basis of Expert Committees’ responses to public comments on proposed revisions. If there is a difference or conflict between the contents of the Commentary and the official text, the official text prevails. For further information, contact: USP Executive Secretariat United States Pharmacopeia 12601 Twinbrook Parkway Rockville, MD 20852-1790 USA Commentary for USP–NF 2021, Issue 1 Comments were received for the following when they were proposed in Pharmacopeial Forum: General
    [Show full text]
  • Chapter 260-70 WAC EQUINE MEDICATION PROGRAM
    Chapter 260-70 Chapter 260-70 WAC EQUINE MEDICATION PROGRAM WAC 12/6/93. Statutory Authority: RCW 67.16.020 and 260-70-500 Definitions applicable to chapter 260-70 WAC. 67.16.040. 84-06-061 (Order 84-01), § 260-70-028, 260-70-510 Equine health and safety. filed 3/7/84.] Repealed by 96-10-001, filed 4/17/96, 260-70-540 Veterinarians' reports. effective 5/18/96. Statutory Authority: RCW 260-70-545 Prohibited practices. 67.16.040. 260-70-550 Medication labeling. 260-70-029 Receiving barn. [Statutory Authority: RCW 67.16.020 260-70-560 Treatment restrictions. and 67.16.040. 84-06-061 (Order 84-01), § 260-70-029, 260-70-570 All horses are subject to inspection. filed 3/7/84.] Repealed by 96-10-001, filed 4/17/96, 260-70-580 Official veterinarian's list. effective 5/18/96. Statutory Authority: RCW 67.16.- 260-70-590 Reporting to the test barn. 040. 260-70-600 Sample collection. 260-70-030 When administration prohibited. [Order 74.1, § 260-70- 260-70-610 Storage and shipment of split samples. 030, filed 5/22/74, effective 7/1/74.] Repealed by 80-01- 260-70-620 Medication restrictions. 072 (Order 79-02), filed 12/24/79. Statutory Authority: 260-70-630 Threshold levels. RCW 67.16.020 and 67.16.040. 260-70-640 Permitted medication. 260-70-031 Reporting to receiving barn. [Statutory Authority: 260-70-645 Anti-ulcer medications. RCW 67.16.020 and 67.16.040. 84-06-061 (Order 84- 260-70-650 Furosemide.
    [Show full text]
  • Pharmacy Program Updates: Quarterly Pharmacy Changes Effective Jan
    Pharmacy Program Updates: Quarterly Pharmacy Changes Effective Jan. 1, 2020 – Part 2 This article is a continuation of the previously published Quarterly Pharmacy Changes Part 1 article. While that part 1 article included the drug list revisions/exclusions, dispensing limits, utilization management changes and general information on pharmacy benefit program updates, this part 2 version contains the more recent coverage additions, utilization management updates and any other updates to the pharmacy program. DRUG LIST CHANGES Based on the availability of new prescription medications and Prime’s National Pharmacy and Therapeutics Committee’s review of changes in the pharmaceuticals market, some additions (new to coverage) and/or some coverage tier changes (drugs moved to a lower out-of-pocket payment level) will be made to the Blue Cross and Blue Shield of New Mexico (BCBSNM) drug lists. Please note: Revisions (drugs still covered but moved to a higher out-of-pocket payment level) and/or exclusions (drugs no longer covered) were included in the Quarterly Pharmacy Changes Part 1 article. Your patient(s) may ask you about therapeutic or lower cost alternatives if their medication is affected by one of these changes. Changes effective Jan. 1, 2020 are outlined below. Drug List Coverage Additions – As of Jan. 1, 2020 Preferred Drug1 Drug Class/Condition Used For Basic, Multi-Tier Basic, Multi-Tier Basic Annual, Enhanced, Enhanced Annual, Multi-Tier Enhanced and Multi-Tier Enhanced Annual Drug Lists BELBUCA (buprenorphine hcl buccal film 75 mcg,
    [Show full text]
  • Potassium Channel Kcsa
    Potassium Channel KcsA Potassium channels are the most widely distributed type of ion channel and are found in virtually all living organisms. They form potassium-selective pores that span cell membranes. Potassium channels are found in most cell types and control a wide variety of cell functions. Potassium channels function to conduct potassium ions down their electrochemical gradient, doing so both rapidly and selectively. Biologically, these channels act to set or reset the resting potential in many cells. In excitable cells, such asneurons, the delayed counterflow of potassium ions shapes the action potential. By contributing to the regulation of the action potential duration in cardiac muscle, malfunction of potassium channels may cause life-threatening arrhythmias. Potassium channels may also be involved in maintaining vascular tone. www.MedChemExpress.com 1 Potassium Channel Inhibitors, Agonists, Antagonists, Activators & Modulators (+)-KCC2 blocker 1 (3R,5R)-Rosuvastatin Cat. No.: HY-18172A Cat. No.: HY-17504C (+)-KCC2 blocker 1 is a selective K+-Cl- (3R,5R)-Rosuvastatin is the (3R,5R)-enantiomer of cotransporter KCC2 blocker with an IC50 of 0.4 Rosuvastatin. Rosuvastatin is a competitive μM. (+)-KCC2 blocker 1 is a benzyl prolinate and a HMG-CoA reductase inhibitor with an IC50 of 11 enantiomer of KCC2 blocker 1. nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg (3S,5R)-Rosuvastatin (±)-Naringenin Cat. No.: HY-17504D Cat. No.: HY-W011641 (3S,5R)-Rosuvastatin is the (3S,5R)-enantiomer of (±)-Naringenin is a naturally-occurring flavonoid.
    [Show full text]